Related Experiment Video
Updated: Jan 28, 2026
07:10
Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
Published on: June 18, 2020
22.7K
Hepatitis A in Poland in 2016
Piotr Polański1, Małgorzata Sadkowska-Todys1
1National Institute of Public Health – National Institute of Hygiene, Department of Epidemiology of Infectious Diseases and Surveillance
Przeglad Epidemiologiczny
|February 28, 2019
Summary
Hepatitis A (HAV) cases decreased in Poland in 2016, but a growing susceptible population heightens epidemic risk, especially among men who have sex with men (MSM). Enhanced surveillance and vaccination promotion are crucial.
Area of Science:
- Epidemiology
- Public Health
- Infectious Disease Surveillance
Background:
- Hepatitis A (HAV) poses a significant public health concern.
- Understanding recent epidemiological trends is vital for effective control strategies.
Purpose of the Study:
- To assess the epidemiological situation of Hepatitis A in Poland during 2016.
- To analyze trends in relation to recent years and identify risk factors.
Main Methods:
- Analysis of national data on infectious diseases and vaccinations in 2016.
- Review of individual case questionnaires and outbreak investigation reports.
- Data compilation from sanitary-epidemiological stations to the NIPH-NIH.
Main Results:
- 35 cases of Hepatitis A were registered in Poland in 2016, with a national incidence of 0.09 per 100,000 population.
- Incidence varied regionally, from 0.03 in Wielkopolskie to 0.28 in podkarpackie voivodeships.
- A decrease in incidence and imported cases was observed compared to the previous year, with slightly higher incidence in males.
Conclusions:
- Despite a decrease in reported cases, a growing susceptible population increases the risk of a future Hepatitis A epidemic in Poland.
- Ongoing large multi-state outbreaks among men who have sex with men (MSM) highlight the need for targeted interventions.
- Enhanced surveillance and vaccination promotion, particularly for at-risk groups, are essential for preventing widespread outbreaks.
Related Concept Videos
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
270
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
270
01:21Hepatic Portal System
5.8K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
5.8K
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
227
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
227
01:16Hepatic Drug Excretion: Influencing Factors
564
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
564
01:14Hepatic Drug Clearance: Role of Transporters
307
In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
307
01:17Hepatic Drug Excretion: Enterohepatic Cycling
2.8K
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
2.8K